Talon battered by 3-month US FDA delay for Marqibo
This article was originally published in Scrip
Executive Summary
Talon Therapeutics' investors panicked on 7 May after the firm disclosed the US FDA delayed its decision by three months on the San Mateo, California-based company's new drug application for Marqibo (vincristine sulfate liposomes injection) as a treatment for adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukaemia (ALL) in second or greater relapse or whose disease has progressed following two or more treatment lines of antileukaemia therapy – with shares plummeting as low as 40%.